Pursuit of a perfect insulin

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Nature reviews. Drug discovery

• Publication date

  2016-03-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrd.2015.36PMID 26988411
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• : A Review of the

  2018cited by this paper
• Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence

  2017cited by this paper
• Hypoglycemia in Diabetes: Pathophysiology, Prevalence, and Prevention

  2016cited by this paper
• Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates

  2015cited by this paper
• Differential Pathway Coupling of the Activated Insulin Receptor Drives Signaling Selectivity by XMetA, an Allosteric Partial Agonist Antibody

  2015cited by this paper
• Agonistic aptamer to the insulin receptor leads to biased signaling and functional selectivity through allosteric modulation

  2015cited by this paper
• One‐year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial

  2015cited by this paper
• Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

  2014cited by this paper
• Use and out-of-pocket costs of insulin for type 2 diabetes mellitus from 2000 through 2010.

  2014cited by this paper
• Hepatoselectivity and the evolution of insulin

  2014cited by this paper
• Chemical synthesis of insulin analogs through a novel precursor.

  2014cited by this paper
• Single‐dose pharmacokinetics and glucodynamics of the novel, long‐acting basal insulin LY2605541 in healthy subjects

  2014cited by this paper
• A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD‐ON)

  2014cited by this paper
• Sanofi to propel inhalable insulin Afrezza into market

  2014cited by this paper
• Oral Insulin Reloaded

  2014cited by this paper
• A 7-year follow-up retrospective, international, multicenter study of insulin pump therapy in children and adolescents with type 1 diabetes

  2014cited by this paper
• Emerging micro- and nanotechnology based synthetic approaches for insulin delivery.

  2014cited by this paper
• Closed-Loop System in the Management of Diabetes: Past, Present, and Future

  2014cited by this paper
• Inhaled insulin: a breath of fresh air? A review of inhaled insulin.

  2014cited by this paper
• Diabetes: Insulin pump therapy for type 2 diabetes mellitus

  2014cited by this paper
• Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?

  2014cited by this paper
• Changes in Glucose and Fat Metabolism in Response to the Administration of a Hepato-Preferential Insulin Analog

  2014cited by this paper
• Proinsulin-Transferrin Fusion Protein as a Novel Long-Acting Insulin Analog for the Inhibition of Hepatic Glucose Production

  2014cited by this paper
• Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects

  2014cited by this paper
• Cell factories for insulin production

  2014cited by this paper
• The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options

  2014cited by this paper
• Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial

  2014cited by this paper
• Identification of a Small Molecular Insulin Receptor Agonist With Potent Antidiabetes Activity

  2014cited by this paper
• Basal insulin analogues in the management of diabetes mellitus: what progress have we made?

  2014cited by this paper
• Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.

  2014cited by this paper
• Contrasting weight changes with LY2605541, a novel long‐acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM

  2014cited by this paper
• A synthetic route to human insulin using isoacyl peptides.

  2014cited by this paper
• PEGylated insulin Lispro, (LY2605541)—a new basal insulin analogue

  2014cited by this paper
• Generation of functional human pancreatic β cells in vitro.

  2014cited by this paper
• Lower Glucose Variability and Hypoglycemia Measured by Continuous Glucose Monitoring With Novel Long-Acting Insulin LY2605541 Versus Insulin Glargine

  2014cited by this paper
• Can Diabetes Be Surgically Cured? Long-Term Metabolic Effects of Bariatric Surgery in Obese Patients with Type 2 Diabetes Mellitus

  2013cited by this paper
• The use of stem cells for pancreatic regeneration in diabetes mellitus

  2013cited by this paper
• Oral Insulin Delivery: How Far are We?

  2013cited by this paper
• Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

  2013cited by this paper
• Concise synthetic routes to human insulin.

  2013cited by this paper
• Responsive materials for self-regulated insulin delivery.

  2013cited by this paper
• FDA dashes Novo's hopes

  2013cited by this paper
• Fully convergent chemical synthesis of ester insulin: determination of the high resolution X-ray structure by racemic protein crystallography.

  2013cited by this paper
• Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes

  2013cited by this paper
• Discovery of high potency, single-chain insulin analogs with a shortened B-chain and nonpeptide linker.

  2013cited by this paper
• An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice.

  2013cited by this paper
• Insulin Pens and New Ways of Insulin Delivery

  2013cited by this paper
• Elderly Patients with Diabetes Experience a Lower Rate of Nocturnal Hypoglycaemia with Insulin Degludec than with Insulin Glargine: A Meta-Analysis of Phase IIIa Trials

  2013cited by this paper
• Glucose-Reducing Effect of the ORMD-0801 Oral Insulin Preparation in Patients with Uncontrolled Type 1 Diabetes: A Pilot Study

  2013cited by this paper
• Combining GLP‐1 receptor agonists with insulin: therapeutic rationales and clinical findings

  2013cited by this paper
• Variability of glucose‐lowering effect as a limiting factor in optimizing basal insulin therapy: a review

  2013cited by this paper
• Superior glycaemic control with once‐daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial

  2013cited by this paper
• Perfusion-decellularized pancreas as a natural 3D scaffold for pancreatic tissue and whole organ engineering.

  2013cited by this paper
• Newer insulin analogs: advances in basal insulin replacement

  2013cited by this paper
• Insulin degludec: overview of a novel ultra long‐acting basal insulin

  2013cited by this paper
• Combining Incretin-Based Therapies With Insulin

  2013cited by this paper
• A history of blood glucose meters and their role in self-monitoring of diabetes mellitus

  2012cited by this paper
• Short‐term intensified insulin treatment in type 2 diabetes: long‐term effects on β‐cell function

  2012cited by this paper
• A Fully Human, Allosteric Monoclonal Antibody That Activates the Insulin Receptor and Improves Glycemic Control

  2012cited by this paper
• Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes

  2012cited by this paper
• Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature

  2012cited by this paper
• Agonism and Antagonism at the Insulin Receptor

  2012cited by this paper
• A Systematic Review of the Literature

  2012cited by this paper
• A constructive debate

  2012cited by this paper
• Therapeutic agents comprising insulin amino acid sequences

  2012cited by this paper
• Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes

  2012cited by this paper
• The role of leptin in glucose homeostasis

  2012cited by this paper
• GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis

  2012cited by this paper
• Anti-obesity drugs: past, present and future

  2012cited by this paper
• Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review

  2012cited by this paper
• Bariatric surgery versus intensive medical therapy in obese patients with diabetes.

  2012cited by this paper
• Insulin Fibrillation and Protein Design: Topological Resistance of Single-Chain Analogs to Thermal Degradation with Application to a Pump Reservoir

  2012cited by this paper
• Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin

  2012cited by this paper
• Insulin-pump therapy for type 1 diabetes mellitus.

  2012cited by this paper
• Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1-30) and GIP(1-42) in high-fat fed mice.

  2011cited by this paper
• Engineering of Insulin Receptor Isoform-Selective Insulin Analogues

  2011cited by this paper
• Insulin Therapy for Management of Type 2 Diabetes Mellitus: Strategies for Initiation and Long-term Patient Adherence

  2011cited by this paper
• Insulin degludec in a flexible daily dosing regimen provides similar glycaemic control without increasing rates of hypoglycaemia compared to dosing the same time daily in type 2 diabetes

  2011cited by this paper
• Closed-loop insulin delivery: from bench to clinical practice

  2011cited by this paper
• Signalling by insulin and IGF receptors: supporting acts and new players.

  2011cited by this paper
• Organization of glucose-responsive systems and their properties.

  2011cited by this paper
• Short-Term Intensive Therapy in Newly Diagnosed Type 2 Diabetes Partially Restores Both Insulin Sensitivity and β-Cell Function in Subjects With Long-Term Remission

  2011cited by this paper
• Comparative review

  2011cited by this paper
• Receptor-isoform-selective insulin analogues give tissue-preferential effects.

  2011cited by this paper
• Design and Folding of [GluA4(OβThrB30)]Insulin (“Ester Insulin”): A Minimal Proinsulin Surrogate that Can Be Chemically Converted into Human Insulin.

  2010cited by this paper
• Backbone cyclic insulin

  2010cited by this paper
• Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial.

  2010cited by this paper
• Insulin pumps: from inception to the present and toward the future

  2010cited by this paper
• Technosphere® Insulin

  2010cited by this paper
• Faculty Opinions recommendation of Design and folding of [GluA4(ObetaThrB30)]insulin ("ester insulin"): a minimal proinsulin surrogate that can be chemically converted into human insulin.

  2010cited by this paper
• Oral insulin – a review of current status

  2010cited by this paper
• Timing of Meal Insulin Boluses to Achieve Optimal Postprandial Glycemic Control in Patients with Type 1 Diabetes

  2010cited by this paper
• The Role of Basal Insulin and Glucagon-Like Peptide-1 Agonists in the Therapeutic Management of Type 2 Diabetes—A Comprehensive Review

  2010cited by this paper
• Insulin analogues with chlorinated amino acids

  2010cited by this paper
• Design and folding of [GluA4(ObetaThrB30)]insulin ("ester insulin"): a minimal proinsulin surrogate that can be chemically converted into human insulin.

  2010cited by this paper
• Practical Aspects of Insulin Pen Devices

  2010cited by this paper
• Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease.

  2009cited by this paper
• Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects.

  2009cited by this paper
• Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties.

  2009cited by this paper
• Halogen-stabilized insulin

  2009cited by this paper

• Molecular engineering of designer diabetes therapeutics.

  2026cites this paper
• From Transient to Stable: Incorporating Electrophiles in Genetically-Encoded and DNA-Encoded Libraries of Peptide-Derived Macrocycles.

  2026cites this paper
• Systemic Pharmacokinetic Principles of Therapeutic Peptides.

  2026cites this paper
• Deciphering the significant impact of natural glycosylation on human insulin

  2025cites this paper
• Winners of the 2024 Tu Youyou Award

  2025cites this paper
• Glucose-Responsive Materials for Smart Insulin Delivery: From Protein-Based to Protein-Free Design

  2025cites this paper
• Amino acid-modified G-quartet hydrogel for glucose-responsive insulin release in vivo.

  2025cites this paper
• International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Insulin and Adjunctive Treatments in Children and Adolescents with Diabetes

  2025cites this paper
• Mapping economic outcomes: how biosimilars enhance access to health systems in Latin America and the Caribbean.

  2025cites this paper
• Long‐term blood glucose control via glucose‐activated transcriptional regulation of insulin analogue in type 1 diabetes mice

  2025cites this paper
• Mechanistic insights and approaches for beta cell regeneration

  2025cites this paper
• Regulation of insulin expression and release in gene and cell therapy of insulin-deficient diabetes.

  2025cites this paper
• Poly(bis(guanidinium)-oxazoline)-Insulin Complex Exerting Long-Acting Glucose-Responsive Insulin Release in Mice and Minipigs.

  2025cites this paper
• A distributional reinforcement learning model for optimal glucose control after cardiac surgery

  2025cites this paper
• Structure–Antimicrobial Activity Relationships of Recombinant Host Defence Peptides Against Drug‐Resistant Bacteria

  2025cites this paper
• Evolution of the Artificial Pancreas: Components and Integration—CGMs, Insulin, and AP Systems

  2025cites this paper
• Non-model bacteria as platforms for endogenous gene expression in synthetic biology

  2025cites this paper
• Long-acting glucose-responsive insulin with swift onset-of-action.

  2025cites this paper
• Integrated individually addressable microneedle arrays for robust glucose monitoring and on-demand insulin releasing

  2025cites this paper
• Evolution of the Artificial Pancreas: Components and Integration—CGMs, Insulin, and AP Systems

  2025cites this paper
• Advances in Peptidomimetics for Next-Generation Therapeutics: Strategies, Modifications, and Applications

  2025cites this paper
• Glyco-based building blocks for the chemical synthesis of glycoproteins.

  2025cites this paper
• Redox investigation of L-A9 peptide and evaluation of its binding with double stranded DNA

  2025cites this paper
• Investigation of cytotoxic effect and action mechanism of a synthetic peptide derivative of rabbit cathelicidin against MDA-MB-231 breast cancer cell line

  2024cites this paper
• Drude2019IDPC polarizable force field reveals structure-function relationship of insulin.

  2024cites this paper
• Application and research progress of MultiBac: A review

  2024cites this paper
• Understanding the Reversible Binding of a Multichain Protein-Protein Complex through Free-Energy Calculations.

  2024cites this paper
• Multi-layered computational gene networks by engineered tristate logics.

  2024cites this paper
• Combinatorial Libraries of Bipodal Binders of the Insulin Receptor

  2024cites this paper
• Transglutaminase 2 in diabetes mellitus: Unraveling its multifaceted role and therapeutic implications for vascular complications

  2024cites this paper
• Toward once-monthly insulin therapy via synergy in two pharmacokinetic protractors: Fc-conjugation and fatty acid acylation

  2024cites this paper
• Site-Specific Histidine Aza-Michael Addition in Proteins Enabled by a Ferritin-Based Metalloenzyme

  2024cites this paper
• Glucose-sensitive insulin with attenuation of hypoglycaemia

  2024cites this paper
• Site-Specific Glyco-Tagging of Native Proteins for the Development of Biologicals

  2024cites this paper
• Amino Acid Compound 2 (AAC2) Treatment Counteracts Insulin-Induced Synaptic Gene Expression and Seizure-Related Mortality in a Mouse Model of Alzheimer’s Disease

  2024cites this paper
• Synthesis of a highly thermostable insulin by phenylalanine conjugation at B29 Lysine

  2024cites this paper
• THPdb2: compilation of FDA approved therapeutic peptides and proteins.

  2024cites this paper
• Insulin Prodrugs with Programmed Chemical Release of an Intramolecular Cross-Link

  2024cites this paper
• Semisynthesis of A6–A11 lactam insulin

  2023cites this paper
• Glucose-Responsive Microgel Comprising Conventional Insulin and Curcumin-Laden Nanoparticles: a Potential Combination for Diabetes Management

  2023cites this paper
• Rational Design and Efficacy of Glucose‐Responsive Insulin Therapeutics and Insulin Delivery Systems by Computation Using Connected Human and Rodent Models

  2023cites this paper
• Simultaneous attenuation of hyperglycemic memory-induced retinal, pulmonary, and glomerular dysfunctions by proinsulin C-peptide in diabetes

  2023cites this paper
• Synthesis of Disulfide Surrogate Peptides through a Serine/Threonine Ligation-Assisted Diaminodiacid Strategy.

  2023cites this paper
• Genetically encoded discovery of perfluoroaryl macrocycles that bind to albumin and exhibit extended circulation in vivo

  2023cites this paper
• Segregation in inhalable powders: Quantification of the effect of vibration on adhesive mixtures.

  2023cites this paper
• In vivo continuous monitoring of peptides and proteins: Challenges and opportunities

  2023cites this paper
• Advances of Smart Stimulus‐Responsive Microneedles in Cancer Treatment

  2023cites this paper
• Supramolecular approaches for insulin stabilization without prolonged duration of action

  2023cites this paper
• Applications of genetic code expansion technology in eukaryotes

  2023cites this paper
• Serine-mediated hydrazone ligation displaying insulin-like peptides on M13 phage pIII.

  2023cites this paper
• ToxinPred 3.0: An improved method for predicting the toxicity of peptides

  2023cites this paper
• A novel opsonic eCIRP inhibitor for lethal sepsis.

  2023cites this paper
• A stepwise activation model for the insulin receptor

  2023cites this paper
• Ca2+-Responsive Glyco-insulin.

  2023cites this paper
• Injectable Systems for Long-lasting Insulin Therapy.

  2023cites this paper
• In Silico Investigation of the Clinical Translatability of Competitive Clearance Glucose-Responsive Insulins.

  2023cites this paper
• Metal-ion coordinated self-assembly of human insulin directs kinetics of insulin release as determined by preclinical SPECT/CT imaging.

  2022cites this paper
• Synthesis and Evaluation of the Insulin–Albumin Conjugate with Prolonged Glycemic Control

  2022cites this paper
• A Porous Reservoir-Backed Boronate Gel Microneedle for Efficient Skin Penetration and Sustained Glucose-Responsive Insulin Delivery

  2022cites this paper
• Formation of Protamine and Zn–Insulin Assembly: Exploring Biophysical Consequences

  2022cites this paper
• Repeated insulin injection without site rotation affects skin thickness – ultrasonographic and histological evaluation

  2022cites this paper
• α/Sulfono-γ-AA peptide hybrids agonist of GLP-1R with prolonged action both in vitro and in vivo

  2022cites this paper
• The basics of noninvasive methods

  2022cites this paper
• Supramolecular Protein Stabilization with Zwitterionic Polypeptide-Cucurbit[7]uril Conjugates.

  2022cites this paper
• The efficacy and safety of GP40081 (insulin aspart biphasic 30) compared with NovoMix® 30 in Type 2 diabetes patients.

  2022cites this paper
• Single-Shot Solid-Phase Synthesis of Full-Length H2 Relaxin Disulfide Surrogates.

  2022cites this paper
• Fibrillation of Human Insulin B-chain by Pulsed Hydrogen Deuterium Exchange Mass Spectrometry.

  2022cites this paper
• Translational aspect in peptide drug discovery and development: An emerging therapeutic candidate

  2022cites this paper
• Factors Affecting Performance of Insulin Pen Injector Technology: A Narrative Review

  2022cites this paper
• Genetically-Encoded Discovery of Perfluoroaryl-Macrocycles that Bind to Albumin and Exhibit Extended Circulation in-vivo

  2022cites this paper
• Construction of a double-responsive modified guar gum nanoparticles and its application in oral insulin administration.

  2022cites this paper
• A Brief Atlas of Insulin.

  2022cites this paper
• A chemoenzymatic strategy for site-selective functionalization of native peptides and proteins

  2022cites this paper
• Celebrating A Century Of Insulin Discovery: A Critical Appraisal Of The Emerging Alternative Insulin Delivery Systems.

  2022cites this paper
• Human pancreatic microenvironment promotes β-cell differentiation via non-canonical WNT5A/JNK and BMP signaling

  2022cites this paper
• Polymer-Based Delivery of Peptide Drugs to Treat Diabetes: Normalizing Hyperglycemia and Preventing Diabetic Complications

  2022cites this paper
• Unconventional insulins from predators and pathogens

  2022cites this paper
• Repurposing pinacol esters of boronic acids for tuning viscoelastic properties of glucose-responsive polymer hydrogels: effects on insulin release kinetics.

  2022cites this paper
• Therapeutic peptides: current applications and future directions

  2022influential citation
• Glucose and H2O2 Dual-Responsive Nanocomplex Grafted with Insulin Prodrug for Blood Glucose Regulation.

  2022cites this paper
• Development of Peptide Biopharmaceuticals in Russia

  2022cites this paper
• Enhanced hexamerization of insulin via assembly pathway rerouting revealed by single particle studies

  2022cites this paper
• Stabilization of a protein by a single halogen‐based aromatic amplifier

  2022cites this paper
• Controlling the fractal dimension in self-assembly of terpyridine modified insulin by Fe2+ and Eu3+ to direct in vivo effects.

  2021cites this paper
• Emerging self-regulated micro/nano drug delivery devices: A step forward towards intelligent diagnosis and therapy

  2021cites this paper
• Recent advances in microneedles-mediated transdermal delivery of protein and peptide drugs

  2021cites this paper
• Insulin and insulin analogs as antidiabetic therapy: A perspective from clinical trials.

  2021cites this paper
• ‘Smart’ insulin-delivery technologies and intrinsic glucose-responsive insulin analogues

  2021cites this paper
• The Chemical Synthesis of Insulin: An Enduring Challenge.

  2021cites this paper
• Identification of the key target profiles underlying the drugs of narrow therapeutic index for treating cancer and cardiovascular disease

  2021cites this paper
• Trends in peptide drug discovery

  2021cites this paper
• Understanding Molecular Mechanism of Biologics Drug Delivery and Stability from NMR Spectroscopy.

  2021cites this paper
• Degradation of insulin amyloid by antibiotic minocycline and formation of toxic intermediates

  2021cites this paper
• Analytical and Biochemical Perspectives of Protein O-GlcNAcylation.

  2021cites this paper
• Cyclodextrins-Peptides/Proteins Conjugates: Synthesis, Properties and Applications

  2021cites this paper
• Amino Acid Nanofibers Improve Glycemia and Confer Cognitive Therapeutic Efficacy to Bound Insulin

  2021influential citation
• Engineering biopharmaceutical formulations to improve diabetes management

  2021cites this paper
• Genetic-code-expanded cell-based therapy for treating diabetes in mice

  2021cites this paper
• Omniligase-1-mediated ligation for insulin analog synthesis in solu-tion and on phage surface

  2021cites this paper
• Structural Stability of Insulin Oligomers and Protein Association-Dissociation Processes: Free Energy Landscape and Universal Role of Water.

  2021cites this paper